BEAM THERAPEUTICS INC

Beam Therapeutics insider buying trend: CEO Evans John M.’s recent 25k share purchase at $23.47 signals disciplined buying amid high buzz, but caution due to valuation concerns.

Beam Therapeutics president moves 123,407 shares into a trust—no market sale, but a signal of insider confidence and family‑wealth planning.